|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
33
|
|
pubmed:dateCreated |
2007-11-20
|
|
pubmed:abstractText |
The clinical outcome of tamoxifen-treated breast cancer patients may be influenced by the activity of cytochrome P450 enzymes that catalyze the formation of antiestrogenic metabolites endoxifen and 4-hydroxytamoxifen. We investigated the predictive value of genetic variants of CYP2D6, CYP2C19, and three other cytochrome P450 enzymes for tamoxifen treatment outcome.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5187-93
|
|
pubmed:meshHeading |
pubmed-meshheading:18024866-Adult,
pubmed-meshheading:18024866-Aged,
pubmed-meshheading:18024866-Aged, 80 and over,
pubmed-meshheading:18024866-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:18024866-Breast Neoplasms,
pubmed-meshheading:18024866-Cytochrome P-450 CYP2D6,
pubmed-meshheading:18024866-Estrogen Antagonists,
pubmed-meshheading:18024866-Female,
pubmed-meshheading:18024866-Gene Frequency,
pubmed-meshheading:18024866-Genotype,
pubmed-meshheading:18024866-Humans,
pubmed-meshheading:18024866-Middle Aged,
pubmed-meshheading:18024866-Mixed Function Oxygenases,
pubmed-meshheading:18024866-Pharmacogenetics,
pubmed-meshheading:18024866-Tamoxifen
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypes.
|
|
pubmed:affiliation |
Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Auerbachstrasse 112, D-70376 Stuttgart, Germany. hiltrud.brauch@ikp-stuttgart.de
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
